mirvetuximab soravtansine

an antineoplastic conjugate of M9346A monoclonal antibody and N2'-deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine that targets folate receptor-alpha

Also Known As:

IMGN-853; IMGN853

Organic Chemicals: 140
- Lactones: 1590
  - Macrolides: 4461
    - Maytansine: 147
      - mirvetuximab soravtansine: 57
Polycyclic Compounds: 7
- Macrocyclic Compounds: 16
  - Macrocyclic Lactams: 28
    - Maytansine: 147
      - mirvetuximab soravtansine: 57
Amino Acids, Peptides, and Proteins: 1
- Proteins: 496323
  - Blood Proteins: 12679
    - Serum Globulins: 555
      - Immunoglobulins: 30911
        Antibodies: 135587
        Monoclonal Antibodies: 57170
        Humanized Monoclonal Antibodies: 220
        mirvetuximab soravtansine: 57
        Immunoconjugates: 3694
        mirvetuximab soravtansine: 57
    - Immunoproteins: 43
      - Immunoglobulins: 30911
        Antibodies: 135587
        Monoclonal Antibodies: 57170
        Humanized Monoclonal Antibodies: 220
        mirvetuximab soravtansine: 57
  - Globulins: 3119
    - Serum Globulins: 555
      - Immunoglobulins: 30911
        Antibodies: 135587
        Monoclonal Antibodies: 57170
        Humanized Monoclonal Antibodies: 220
        mirvetuximab soravtansine: 57
        Immunoconjugates: 3694
        mirvetuximab soravtansine: 57
Chemical Actions and Uses
- Pharmacologic Actions: 164
  - Physiological Effects of Drugs: 1
    - Immunologic Factors: 8207
      - Immunoconjugates: 3694
        mirvetuximab soravtansine: 57

Kelli L Running Selected Research

Kelli L Running Research Topics

Disease

Drug/Important Bio-Agent (IBA)